180 related articles for article (PubMed ID: 2243335)
1. Modulation of ATP-sensitive K+ channel activity and contractile behavior in mammalian ventricle by the potassium channel openers cromakalim and RP49356.
Ripoll C; Lederer WJ; Nichols CG
J Pharmacol Exp Ther; 1990 Nov; 255(2):429-35. PubMed ID: 2243335
[TBL] [Abstract][Full Text] [Related]
2. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Nielsen-Kudsk JE
Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
[TBL] [Abstract][Full Text] [Related]
3. Cross tolerance between cromakalim and RP49356 in the uterus of the rat in vivo and in vitro.
Piper I; Downing SJ; Hollingsworth M
Eur J Pharmacol; 1992 Sep; 219(3):347-53. PubMed ID: 1425963
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
5. The contribution of Rb-permeable potassium channels to the relaxant and membrane hyperpolarizing actions of cromakalim, RP49356 and diazoxide in bovine tracheal smooth muscle.
Longmore J; Bray KM; Weston AH
Br J Pharmacol; 1991 Apr; 102(4):979-85. PubMed ID: 1855127
[TBL] [Abstract][Full Text] [Related]
6. Potassium channel openers act through an activation of ATP-sensitive K+ channels in guinea-pig cardiac myocytes.
Escande D; Thuringer D; Le Guern S; Courteix J; Laville M; Cavero I
Pflugers Arch; 1989 Sep; 414(6):669-75. PubMed ID: 2510125
[TBL] [Abstract][Full Text] [Related]
7. Apparent competition between ATP and the potassium channel opener RP 49356 on ATP-sensitive K+ channels of cardiac myocytes.
Thuringer D; Escande D
Mol Pharmacol; 1989 Dec; 36(6):897-902. PubMed ID: 2601686
[TBL] [Abstract][Full Text] [Related]
8. RP 49356 and cromakalim relax airway smooth muscle in vitro by opening a sulphonylurea-sensitive K+ channel: a comparison with nifedipine.
Raeburn D; Brown TJ
J Pharmacol Exp Ther; 1991 Feb; 256(2):480-5. PubMed ID: 1899701
[TBL] [Abstract][Full Text] [Related]
9. Effects of cromakalim, RP49356, diazoxide, glibenclamide and galanin in rat portal vein.
Longmore J; Newgreen DT; Weston AH
Eur J Pharmacol; 1990 Nov; 190(1-2):75-84. PubMed ID: 1706274
[TBL] [Abstract][Full Text] [Related]
10. Glyburide-sensitive K+ channels in cultured rat hippocampal neurons: activation by cromakalim and energy-depleting conditions.
Politi DM; Rogawski MA
Mol Pharmacol; 1991 Aug; 40(2):308-15. PubMed ID: 1715018
[TBL] [Abstract][Full Text] [Related]
11. Two different types of potassium channels in human skeletal muscle activated by potassium channel openers.
Quasthoff S; Franke C; Hatt H; Richter-Turtur M
Neurosci Lett; 1990 Nov; 119(2):191-4. PubMed ID: 2126363
[TBL] [Abstract][Full Text] [Related]
12. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
13. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.
Pratz J; Mondot S; Montier F; Cavero I
J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538
[TBL] [Abstract][Full Text] [Related]
14. Mechanical and energetic effects of cromakalim on guinea pig left ventricular papillary muscle.
Joseph T; Coirault C; Ducros L; Lecarpentier Y
J Pharmacol Exp Ther; 1996 Nov; 279(2):464-71. PubMed ID: 8930147
[TBL] [Abstract][Full Text] [Related]
15. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
17. Effect of temperature on the activation of myocardial KATP channel in guinea pig ventricular myocytes: a pilot study by whole cell patch clamp recording.
Jin SQ; Niu LJ; Deng CY; Yao ZB; Zhou YJ
Chin Med J (Engl); 2006 Oct; 119(20):1721-6. PubMed ID: 17097020
[TBL] [Abstract][Full Text] [Related]
18. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
19. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
20. K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation.
Ford WR; Lopaschuk GD; Schulz R; Clanachan AS
Br J Pharmacol; 1998 Jun; 124(4):639-46. PubMed ID: 9690854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
